Hepatocellular carcinoma, the predominant form of primary liver cancer, is notorious for its resistance to conventional treatment and high mortality rates. Tumors thrive in hypoxic environments created by inadequate vascularization, which in turn activates a series of adaptive cellular programs. One such adaptation involves the modulation of protein stability and degradation systems, notably the ubiquitin-proteasome pathway, a critical regulator of protein turnover. The study pivots on USP13, a ubiquitin-specific protease, highlighting its pivotal role under hypoxic stress in sustaining cancer cell viability.

Central to this newfound mechanism is the stabilization of ATP citrate lyase (ACLY), a key metabolic enzyme that catalyzes the production of cytosolic acetyl-CoA, a building block for lipid biosynthesis. The overexpression of USP13 under hypoxia protects ACLY from ubiquitin-mediated degradation, thereby sustaining the metabolic flux necessary for membrane synthesis and energy production. This biochemical preservation enhances the cancer cells’ resilience, particularly by counteracting ferroptosis—an iron-dependent, lipid peroxidation-driven form of programmed cell death increasingly recognized as a vulnerability in malignancies.

Ferroptosis resistance emerges as a critical survival advantage for HCC cells. Under normal circumstances, cells facing oxidative stress succumb to ferroptosis, which is crucial for eliminating damaged or malignant cells. However, by stabilizing ACLY, USP13 enables the tumor cells to maintain their lipid metabolism homeostasis, diminishing lipid peroxidation and effectively shutting down ferroptotic pathways. This insight reveals an intimate metabolic-enzymatic crosstalk that cancer cells exploit to circumvent intrinsic cell death processes that would otherwise curtail their expansion.

Moreover, the study delves into the immunological implications of USP13-mediated ferroptosis resistance. Tumor immune evasion remains a formidable barrier to durable cancer remission. The hypoxia-induced USP13 expression not only safeguards tumor cells from death but also hinders their recognition by immune cells. The stabilization of ACLY fosters a microenvironment less conducive to immune infiltration and cytotoxic response, allowing cancer cells to escape immune surveillance. This dual role of USP13 underscores its potential as a therapeutic target, where inhibition could disrupt both metabolic resilience and immune evasion.

Advanced molecular techniques were employed to dissect this pathway. Hu and colleagues utilized hypoxia-mimetic conditions in HCC cell cultures to simulate the low oxygen milieu of solid tumors. Proteomic analyses revealed significant upregulation of USP13, followed by co-immunoprecipitation experiments that demonstrated its direct interaction with ACLY. Subsequent ubiquitination assays confirmed USP13’s deubiquitinating activity, effectively shielding ACLY from proteasomal degradation. The robustness of these findings was further substantiated by in vivo tumor models exhibiting reduced growth and increased ferroptosis markers following USP13 knockdown.

This study’s implications ripple through the broader landscape of cancer metabolism and immunology. It echoes the growing recognition that tumor metabolism is not merely a consequence of malignant transformation but a driving force enabling cancer persistence and progression. The USP13-ACLY axis exemplifies how metabolic enzymes and protein stability regulators interlock to sculpt cancer’s survival toolkit. Additionally, it positions ferroptosis as a therapeutic frontier, where tipping the balance toward lipid peroxidation-induced death could sensitize tumors to existing and emerging treatments.

Intriguingly, the findings may have translational potential beyond hepatocellular carcinoma. Given that hypoxia and evasion of cell death are hallmarks of many solid tumors, the USP13-driven ferroptosis resistance mechanism might be conserved in other cancer types. This opens up exciting prospects for the development of USP13 inhibitors or combination therapies that simultaneously disrupt metabolic and immune evasion pathways.

Tumor immunotherapy, a rapidly evolving field, might particularly benefit from these insights. The study implies that combining ferroptosis sensitizers with immune checkpoint inhibitors could overcome the immunosuppressive tumor microenvironment characteristic of hypoxic tumors. By reinstating ferroptotic cell death, immune cells may gain better access and efficacy, overcoming tumor-induced immune deserts.

Furthermore, this discovery underscores the intricate interplay between hypoxia signaling pathways, ubiquitination dynamics, and metabolic reprogramming. Hypoxia-inducible factors (HIFs) likely facilitate USP13 transcriptional activation, linking oxygen sensing to post-translational modification landscapes. This multilayered regulation exemplifies cancer’s adaptive plasticity, which has long stymied durable therapeutic outcomes.

The research team also explored pharmacological avenues to exploit this knowledge. Small-molecule inhibitors targeting USP13’s catalytic activity were tested, resulting in increased ACLY ubiquitination, diminished tumor cell viability, and enhanced ferroptosis markers under hypoxic conditions. These experimental interventions illuminate a path toward viable therapeutics that may complement existing treatment modalities, particularly in treatment-resistant HCC.

Importantly, this work enriches the nuanced understanding of ferroptosis regulation—in particular, how metabolic enzyme stabilization serves as a firewall against oxidative cell death. While ferroptosis has been recognized as a promising anti-cancer mechanism, cancer cells’ ability to modulate metabolic enzyme stability through deubiquitination adds a sophisticated layer of resistance, previously underappreciated.

The oncological community often grapples with the paradox of targeting pathways that are essential for normal cellular functions. The preferential upregulation of USP13 in hypoxic tumor cells may afford a therapeutic window, minimizing detrimental effects on normal tissue. This selective vulnerability could be exploited to design treatments with higher efficacy and reduced systemic toxicity.

The comprehensive nature of the study—spanning molecular biology, biochemistry, and immunology—exemplifies the interdisciplinary approach required to decode cancer biology’s complexities. It sets a benchmark for future research scrutinizing ubiquitination’s role in metabolic regulation within the tumor microenvironment.

As the fight against hepatocellular carcinoma continues, this discovery urges a reexamination of ferroptosis-targeted therapies with an emphasis on enzyme stabilization pathways. Clinicians and researchers may soon witness innovative treatments that disrupt cancer’s defense mechanisms at a molecular level, turning the tide against one of the most lethal malignancies worldwide.

In summary, Hu, Li, Chen, and their collaborators have charted a compelling narrative of how hypoxia-induced USP13 expression empowers hepatocellular carcinoma cells to resist ferroptotic death and evade immune destruction through the stabilization of ACLY. This revelation not only enriches our understanding of cancer biology but also beckons the development of novel, targeted interventions poised to disrupt tumor survival in its tracks. As further investigations unfold, the therapeutic landscape for HCC and possibly other hypoxic solid tumors may undergo a transformative evolution.

Subject of Research: Mechanisms of ferroptosis resistance and tumor immune evasion driven by hypoxia-induced USP13 expression in hepatocellular carcinoma via ACLY stabilization.

Article Title: Hypoxia-induced USP13 expression drives ferroptosis resistance and tumor immune evasion in hepatocellular carcinoma through the stabilization of ACLY.

Article References:
Hu, K., Li, J., Chen, K. et al. Hypoxia-induced USP13 expression drives ferroptosis resistance and tumor immune evasion in hepatocellular carcinoma through the stabilization of ACLY. Cell Death Discov. (2025). https://doi.org/10.1038/s41420-025-02869-z

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02869-z

Long non-coding RNAs have emerged as master regulators in cancer biology, influencing gene expression without translating into proteins. Among these, TUG1 has garnered attention for its aberrant expression across various tumors. Despite initial indications of its involvement in HCC, the precise molecular pathways through which TUG1 exacerbates liver cancer remained elusive until the current investigation. The study leverages clinical data, bioinformatics, and state-of-the-art laboratory assays to map the oncogenic landscape sculpted by TUG1 in HCC.

The researchers first embarked on comprehensive expression analyses using RT-qPCR, supplemented by mining large-scale sequencing datasets from GEO and TCGA repositories. These analyses revealed a consistent and significant upregulation of TUG1 in HCC tissues compared to healthy liver counterparts, with the highest expression levels correlating with more advanced clinical stages. Notably, this upregulation of TUG1 tightly paralleled the increased expression of programmed death-ligand 1 (PD-L1), a well-documented immune checkpoint protein notorious for enabling tumor cells to escape immune surveillance.

The connection between TUG1 and PD-L1 emerged as a compelling axis in HCC immunobiology. PD-L1’s role in dampening the host immune response, particularly by impairing CD8+ cytotoxic T lymphocytes, is a cornerstone of tumor immune evasion. By demonstrating a positive correlation between TUG1 levels and PD-L1 expression, the study proposed that TUG1 may be a key upstream regulator of immune checkpoint dynamics in liver cancer.

Functionally, the team conducted a series of in vitro assays to interrogate the impact of TUG1 on HCC cell behavior and immune interactions. These included the Cell Counting Kit-8 (CCK8) for measuring proliferation, colony formation assays to assess clonogenic potential, and transwell assays to evaluate invasive capacity. Elevated TUG1 expression consistently augmented these oncogenic traits, fostering more aggressive cellular phenotypes. Conversely, silencing TUG1 drastically curtailed proliferation and invasion, underscoring its role as a facilitator of tumor growth.

Immunologically, the researchers performed co-culture experiments between HCC cells and CD8+ T cells to assess cytotoxic efficacy. Strikingly, HCC cells with reduced TUG1 expression became more susceptible to CD8+ T cell-mediated killing, an effect that aligned with decreased PD-L1 levels. This finding illuminated TUG1 as a molecular shield protecting cancer cells from immune attack, directly linking its expression to compromised antitumor immunity.

The study further investigated how TUG1 exerts its regulatory influence on PD-L1. Using dual-luciferase reporter assays, the team demonstrated that TUG1 acts as a competitive endogenous RNA (ceRNA), or “sponge,” for microRNA miR-377-3p. Under normal conditions, miR-377-3p binds to the 3′ untranslated region of PD-L1 mRNA, restricting its translation. However, TUG1 sequesters miR-377-3p, freeing PD-L1 mRNA from repression and enabling its overexpression. This molecular interplay delineates a finely tuned post-transcriptional control mechanism promoting immune evasion.

An immensely significant aspect of the study involves lenvatinib (LEN), a tyrosine kinase inhibitor approved for advanced HCC treatment. While LEN displays notable antitumor activity, resistance often emerges, fueled by complex molecular circuits. The researchers found that LEN treatment of HCC cells substantially suppressed both TUG1 and PD-L1 expression, thereby enhancing CD8+ T cell-mediated cytotoxicity against tumor cells. This observation proposed that LEN not only disrupts oncogenic signaling but also revitalizes antitumor immune responses by downregulating key immune checkpoint modulators.

Critically, the overexpression of TUG1 in HCC cells diminished LEN’s cytotoxic impact, effectively dampening the drug’s therapeutic potential. In contrast, targeted knockdown of TUG1 synergized with LEN treatment, producing a remarkable decrease in tumor cell viability and improved immune-mediated clearance. These findings unfold the possibility that TUG1 expression status could serve as a predictive biomarker for LEN responsiveness while positioning TUG1 as an adjuvant therapeutic target.

To translate these insights beyond the petri dish, the authors conducted in vivo experiments using xenograft mouse models of HCC. The combination of TUG1 knockdown and LEN administration significantly retarded tumor growth compared to either treatment alone. Correspondingly, tumor specimens from treated animals exhibited heavily reduced PD-L1 expression and increased infiltration of cytotoxic CD8+ T cells, confirming the in vitro mechanistic model. This powerful preclinical evidence strengthens the rationale for targeting TUG1 to enhance existing therapies.

Beyond illuminating the molecular dance between TUG1, miR-377-3p, and PD-L1, this research sets the stage for novel interventional strategies in HCC. Targeted silencing of TUG1 could disrupt tumor immune escape, revitalizing endogenous anticancer immunity while boosting the efficacy of frontline drugs like lenvatinib. Such dual benefits could address the pressing problem of therapeutic resistance and improve patient survival outcomes.

The implications of these findings extend beyond hepatocellular carcinoma alone, as similar lncRNA-mediated immune regulatory pathways might operate in other solid tumors. The paradigm of lncRNA sponge activity modulating checkpoint proteins presents fertile ground for future oncology research and drug development. Harnessing intricacies of RNA-mediated gene expression control could revolutionize immunotherapy approaches.

This study also accentuates the importance of integrating transcriptomic data with functional immunology to unravel the complex regulatory networks underpinning cancer progression. By combining high-throughput bioinformatics analyses and rigorous laboratory validations, the team exemplifies contemporary translational cancer research that can bridge bench-to-bedside gaps.

In conclusion, the discovery that TUG1 fosters HCC progression through miR-377-3p sponging and subsequent PD-L1 upregulation not only enriches our molecular understanding of liver cancer but opens new avenues for therapeutic intervention. Targeting TUG1 emerges as a promising strategy to potentiate cancer immunosurveillance and enhance the clinical utility of lenvatinib, potentially transforming the treatment landscape for this devastating disease.

As global oncology shifts toward precision medicine, such insights underscore the necessity of exploring lncRNAs as both biomarkers and drug targets. Continued investigation into TUG1 and its regulatory networks will be crucial to developing next-generation therapeutics that more effectively combat hepatocellular carcinoma and possibly other malignancies resistant to conventional treatment.

Subject of Research: Hepatocellular carcinoma, long non-coding RNA TUG1, PD-L1 immune checkpoint, miR-377-3p interaction, lenvatinib efficacy

Article Title: TUG1 targeting enhances anticancer immunity thereby facilitating lenvatinib efficacy in hepatocellular carcinoma

Article References:
Che, S., He, L., Chen, Q. et al. TUG1 targeting enhances anticancer immunity thereby facilitating lenvatinib efficacy in hepatocellular carcinoma. Genes Immun (2025). https://doi.org/10.1038/s41435-025-00358-y

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41435-025-00358-y

Keywords: Hepatocellular carcinoma, long non-coding RNA, TUG1, PD-L1, immune evasion, miR-377-3p, lenvatinib, cancer immunotherapy, RNA sponging, tumor microenvironment

A groundbreaking study from researchers at Chongqing Medical University unravels the intricate molecular interplay involving the fatty acid transport protein, SLC27A5, and its profound influence on liver cancer stemness. As a liver-specific solute carrier primarily involved in hepatic fatty acid metabolism, SLC27A5 deficiency has been linked to hepatic fibrosis and progression of hepatocellular carcinoma. Intriguingly, beyond its metabolic functions, SLC27A5 has been implicated in RNA-related regulatory pathways, particularly alternative polyadenylation (APA), a post-transcriptional mechanism that diversifies mRNA isoforms through differential cleavage and polyadenylation sites, thereby impacting gene expression regulation.

Alternative polyadenylation represents a pivotal control point in mRNA maturation, generating transcripts with varied 3′ untranslated region (3′-UTR) lengths. This diversity influences mRNA stability, localization, and translational efficiency, often modulating gene expression patterns implicated in oncogenesis. Aberrations in APA dynamics have been documented in numerous cancers, including HCC, highlighting the role of RNA processing dysregulation in tumor biology. Building on previous evidence linking SLC27A5 to RNA processes, the current study sought to delineate its role in modulating APA and elucidate mechanisms through which it impacts liver cancer stem cell biology.

Deploying an integrative screening approach combining immunoprecipitation coupled with mass spectrometry (IP-MS), the researchers identified compelling interactions between SLC27A5 and poly(A)-binding protein cytoplasmic 1 (PABPC1). PABPC1 is a multifaceted RNA-binding protein that shuttles between the nucleus and cytoplasm, playing an instrumental role in mediating 3′UTR-APA and mRNA stability. Notably, PABPC1 is overexpressed in various malignancies and is correlated with poor prognostic outcomes in HCC patients. The identification of SLC27A5-PABPC1 interaction reflects a novel regulatory axis in the post-transcriptional control of gene expression, with broad implications for cancer stemness regulation.

Subsequent mechanistic investigations revealed that SLC27A5 promotes the ubiquitination and proteasomal degradation of PABPC1 via the recruitment of RBBP7, an epigenetic regulator and protein degrader. This degradation of PABPC1 culminates in significant downregulation of its cellular levels, effectively reshaping the landscape of APA regulatory machinery in HCC cells. By tempering PABPC1 abundance, SLC27A5 indirectly influences the APA profile of downstream target transcripts critical for stemness and tumor progression.

A key downstream effector identified in this regulatory cascade is METTL14, an RNA methyltransferase involved in N6-methyladenosine (m6A) modification of mRNA, with established roles in modulating RNA metabolism and cancer cell biology. The study found that SLC27A5, through the repression of PABPC1, modulates the usage frequency of METTL14 distal polyadenylation sites (dPAS), resulting in a switch from transcripts harboring longer 3′UTRs (METTL14-UL) to shorter ones (METTL14-US). Remarkably, this alteration in METTL14 isoform expression is independent of its methyltransferase enzymatic activity, prompting reconsideration of METTL14’s functions beyond catalysis.

Bioinformatics analyses underscored a negative correlation between METTL14 expression and liver cancer stemness markers, supporting the hypothesis that METTL14 isoforms exert differential influences on HCC stem cell traits. Both in vitro cellular assays and in vivo mouse models demonstrated that METTL14-US effectively suppresses stemness phenotypes in HCC. Importantly, SLC27A5 upregulates METTL14-US expression, thereby unleashing its tumor-suppressive capacity and further inhibiting cancer stem cell properties. This regulatory axis highlights the pivotal role of APA in fine-tuning isoform-specific gene function within the tumor microenvironment.

Additional mechanistic insights revealed that METTL14-US mRNA evades microRNA-mediated silencing pathways, affording enhanced transcript stability and sustained expression levels. By contrast, METTL14-UL transcripts with longer 3′UTRs are more susceptible to miRNA targeting, thereby reducing their steady-state abundance. This differential vulnerability reinforces the critical impact of APA-generated isoforms in post-transcriptional gene regulation and tumor biology, further substantiating the therapeutic potential of manipulating APA profiles.

Corroborating these molecular findings, analysis of human HCC specimens revealed that SLC27A5 deficiency correlates with elevated PABPC1 levels and a predominance of short 3′UTR METTL14 isoforms, collectively driving diminished METTL14 function and exacerbated tumor progression. These observations validate the clinical relevance of the SLC27A5-PABPC1-METTL14 axis and underscore its potential as a biomarker for HCC prognosis and treatment stratification.

This study’s revelations about the SLC27A5-mediated regulation of liver cancer stemness via alternative polyadenylation not only deepen our comprehension of the molecular networks governing hepatic tumor biology but also open novel avenues for therapeutic intervention. Targeting components of this axis, particularly the restoration of SLC27A5 function or modulation of METTL14 alternative polyadenylation patterns, could yield innovative strategies to curtail cancer stem cell-driven tumor relapse and metastasis in HCC.

In conclusion, the elucidation of the SLC27A5-PABPC1-METTL14 axis represents a paradigm shift in understanding the convergence of metabolic regulation, RNA processing, and cancer stem cell biology. The findings highlight the profound implications of alternative polyadenylation in oncogenesis, transcending conventional gene expression paradigms, and offer promising new therapeutic targets in the relentless fight against hepatocellular carcinoma. As the field advances, clinical translation of these insights could herald a new era of precision medicine tailored to dismantle cancer stem cell reservoirs and improve patient outcomes.

Subject of Research: Hepatocellular carcinoma; liver cancer stem cells; post-transcriptional regulation; alternative polyadenylation; RNA-binding proteins; SLC27A5; PABPC1; METTL14.

Article Title: SLC27A5 inhibits cancer stem cells by inducing alternative polyadenylation of METTL14 in hepatocellular carcinoma

Web References: http://dx.doi.org/10.1016/j.gendis.2024.101488

References: Original publication in Genes & Diseases, doi: 10.1016/j.gendis.2024.101488

Image Credits: Genes & Diseases

Keywords: Cancer stem cells, hepatocellular carcinoma, SLC27A5, PABPC1, METTL14, alternative polyadenylation, post-transcriptional regulation, RNA-binding proteins, ubiquitination, liver cancer stemness